About us

Leadership

Executive Team

Sanjay Keswani, MBBS, FRCP

President and Chief Executive Officer

Dr Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech. He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Sanjay was Senior Vice President of R&D at Hoffman La Roche, a...
Read more >>

Dr Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech. He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Sanjay was Senior Vice President of R&D at Hoffman La Roche, and Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology. He has held CEO and CMO positions in biotech with experience of successful Nasdaq IPO (Annexon), acquisition (MiroBio by Gliead), venture fundraising (Series A, B, D rounds), and multiple industry partnerships. Sanjay has been instrumental in the development of several approved medicines, including Risdiplam, Emgality, Faricimab, Cymbalta, Aimovig and Deucravacitnib. Sanjay completed his residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at Johns Hopkins. He graduated in medicine at St. Bartholomew’s Hospital (UK’s oldest hospital founded in 1123) and holds a First Class honors BSc degree from St. Mary’s Hospital, London in Pathology & Basic Medical Sciences (Immunology).

Prof. Michal Schwartz

Co-founder and Chief Scientific Officer

A world-renowned expert in Neuroimmunology who pioneered the field of nervous system repair, protection, and maintenance by the immune system. Schwartz is a professor of Neuroimmunology at the Weizmann Institute of Science (WIS). She was the first to suggest, against the prevailing dogma at the time, that circulating immune cells are e...
Read more >>

A world-renowned expert in Neuroimmunology who pioneered the field of nervous system repair, protection, and maintenance by the immune system. Schwartz is a professor of Neuroimmunology at the Weizmann Institute of Science (WIS). She was the first to suggest, against the prevailing dogma at the time, that circulating immune cells are essential for supporting life-long functional brain plasticity in health and disease, and should be harnessed to help fighting brain pathologies. These results led to the paradigm-shifting approach of developing an immunotherapy to combat neurodegenerative diseases. Her scientific publications have been extremely influential, as reflected by their high citation scores. Schwartz has received numerous national and international awards, and served as president of the International Society of Neuroimmunology (2016-2018).

Roee Hevrony

Chief Financial Officer and Head of Business Development

Prior to joining ImmunoBrain in 2015, Roee worked for Babcock Power, Inc. in its nuclear power generation unit as a business controller and started his career as an investment banker with Merrill Lynch. Roee holds a bachelor’s degree in Economics from Columbia University (magna cum laude) and an MBA from the Wharton School of the Unive...
Read more >>

Prior to joining ImmunoBrain in 2015, Roee worked for Babcock Power, Inc. in its nuclear power generation unit as a business controller and started his career as an investment banker with Merrill Lynch. Roee holds a bachelor’s degree in Economics from Columbia University (magna cum laude) and an MBA from the Wharton School of the University of Pennsylvania.

Eti Yoles, Ph.D.

Chief Operating Officer

Dr. Eti Yoles brings over 20 years of experience in biotechnology, specializing in neuro-immunology. She has held key management positions in biotech startups, including CSO at Immunobrain Therapies and Managing Director at NeuroQuest. Dr. Yoles holds a B.Sc. in Biology, M.Sc. in Physiology, and Ph.D. in Neurobiology from Bar Ilan Univ...
Read more >>

Dr. Eti Yoles brings over 20 years of experience in biotechnology, specializing in neuro-immunology. She has held key management positions in biotech startups, including CSO at Immunobrain Therapies and Managing Director at NeuroQuest. Dr. Yoles holds a B.Sc. in Biology, M.Sc. in Physiology, and Ph.D. in Neurobiology from Bar Ilan University.

Tommaso Croese, MD

Head of Clinical Development

Tommaso is a Neurologist with extensive experience in neuroimmunology, focusing on the role of immune cells in neurological disorders such as Multiple Sclerosis and Alzheimer’s Disease. His expertise is backed by over 10 years in preclinical model research, shaping a deeper understanding of these diseases. After completing his residenc...
Read more >>

Tommaso is a Neurologist with extensive experience in neuroimmunology, focusing on the role of immune cells in neurological disorders such as Multiple Sclerosis and Alzheimer’s Disease. His expertise is backed by over 10 years in preclinical model research, shaping a deeper understanding of these diseases. After completing his residency in neurology at San Raffaele Hospital in Milan, Tommaso pursued his PhD at the Weizmann Institute of Science, further enriching his clinical and research capabilities. During his PhD, he authored numerous scientific papers, underscoring the interaction between the brain and the immune system.

Sharona Raveh, Ph.D., MBA

VP Manufacturing and Product Development

Over 20 years of experience in global biopharmaceutical companies, running operations and R&D teams, leading CMC and CMO activities from early phase development through commercial production.  Sharona served as Senior Director, Head of Bio-Analytical Development, CMC Biosimilars for Teva Pharmaceuticals. Prior to that Sharona was D...
Read more >>

Over 20 years of experience in global biopharmaceutical companies, running operations and R&D teams, leading CMC and CMO activities from early phase development through commercial production.  Sharona served as Senior Director, Head of Bio-Analytical Development, CMC Biosimilars for Teva Pharmaceuticals. Prior to that Sharona was Director of Analytical Development and CMC project manager in BTG, Ferring. Sharona holds an M.SC. from Ben-Gurion University, Ph.D from PARIS VI University and Pasteur Institute in protein engineering, structure and function and MBA in management and business psychology from The college of management.

Kuti Baruch, Ph.D.

VP Research and Development

Neuroimmunologist with over 15 years of biomedical experience in developing therapeutic approaches to neurodegenerative conditions. Kuti joined ImmunoBrain when the company was founded, following licensing of the technology that was developed at the Weizmann Institute of Science in his Ph.D. and Postdoctoral studies at Prof. Schwartz’s...
Read more >>

Neuroimmunologist with over 15 years of biomedical experience in developing therapeutic approaches to neurodegenerative conditions. Kuti joined ImmunoBrain when the company was founded, following licensing of the technology that was developed at the Weizmann Institute of Science in his Ph.D. and Postdoctoral studies at Prof. Schwartz’s laboratory. Kuti holds a M.Sc. in Medical Science from Tel-Aviv University, and a Ph.D. in Neurobiology from the Weizmann Institute of Science.

Dalia Bracha, RN, BSN, MPA

VP Clinical Management and Operations

An experienced clinical Project Manager with more than 22 years of demonstrated management of global clinical studies (phase I-IV) across the US, EU and Israel, having worked across large global pharmaceuticals, CRO and emerging biotech companies.

An experienced clinical Project Manager with more than 22 years of demonstrated management of global clinical studies (phase I-IV) across the US, EU and Israel, having worked across large global pharmaceuticals, CRO and emerging biotech companies.

Ronit Monin, MPharm, MPH

Head of Regulatory Affairs

A regulatory affair professional with over 20 years of hands-on experience in the clinical development of innovative medicinal products across a number of therapeutic areas. In-depth understanding of regulatory requirements for the development of drug-device combination products, drugs and biologics from early phase development through...
Read more >>

A regulatory affair professional with over 20 years of hands-on experience in the clinical development of innovative medicinal products across a number of therapeutic areas. In-depth understanding of regulatory requirements for the development of drug-device combination products, drugs and biologics from early phase development through to phase 3 trials and subsequent NDA and MAA.

Our Advisory Board

Dr. Jan Egebjerg, Ph.D

SVP Grants and Prizes Lundbeckfoundation. Previously Senior Director of Neurodegeneration at Janssen since 2018. Previously he was Divisional Director for Neurodegeneration at H. Lundbeck A/S and ass. professor at Dept for Molecular Biology, University of Aarhus.

SVP Grants and Prizes Lundbeckfoundation. Previously Senior Director of Neurodegeneration at Janssen since 2018. Previously he was Divisional Director for Neurodegeneration at H. Lundbeck A/S and ass. professor at Dept for Molecular Biology, University of Aarhus.

Philip Scheltens, MD

Since 2000, Dr Scheltens is Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam.

Since 2000, Dr Scheltens is Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam.

Lon Schneider, MD

Professor of Psychiatry and Behavioral Sciences. Director of the California Alzheimer’s Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer's Disease Research Center (National Institutes of Health)....
Read more >>

Professor of Psychiatry and Behavioral Sciences. Director of the California Alzheimer’s Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer's Disease Research Center (National Institutes of Health).

George Garibaldi, MD

Dr. Garibaldi has more than 25 years of global pharmaceutical and academic experience in early to late-stage drug development. Previously Vice President of Neuroscience and Product Development at Hoffmann-La Roche AG.

Dr. Garibaldi has more than 25 years of global pharmaceutical and academic experience in early to late-stage drug development. Previously Vice President of Neuroscience and Product Development at Hoffmann-La Roche AG.

Michael Davidson, MD

Professor of Psychiatry at the Sackler School of Medicine Tel Aviv and Mount Sinai School of Medicine NYC . Currently Executive President of the Alzheimer Center in Tel Aviv, an organization providing inpatient and community  care to several hundred demented elderly.

Professor of Psychiatry at the Sackler School of Medicine Tel Aviv and Mount Sinai School of Medicine NYC . Currently Executive President of the Alzheimer Center in Tel Aviv, an organization providing inpatient and community  care to several hundred demented elderly.

Moses Chao, Ph.D

Professor, New York University School of Medicine. His laboratory defined the genes encoding the nerve growth factor receptor and his research interests are in defining mechanisms used by trophic factors to change synaptic plasticity.

Professor, New York University School of Medicine. His laboratory defined the genes encoding the nerve growth factor receptor and his research interests are in defining mechanisms used by trophic factors to change synaptic plasticity.

Paul Aisen, MD

Professor of Neurology; Director, Alzheimer’s Therapeutic Research Institute, University of Southern California.

Professor of Neurology; Director, Alzheimer’s Therapeutic Research Institute, University of Southern California.

Board of Directors

Mr. Nathan Hevrony

Founder and Executive Chairman of ImmunoBrain Checkpoint. An entrepreneur and private equity investor with 40 years experience in financing and M&A in industrial and biotechnology companies. Serves as a director and trustee in public and private enterprises.

Founder and Executive Chairman of ImmunoBrain Checkpoint. An entrepreneur and private equity investor with 40 years experience in financing and M&A in industrial and biotechnology companies. Serves as a director and trustee in public and private enterprises.

Sanjay Keswani, MBBS, FRCP

Dr Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech. He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Sanjay was Senior Vice President of R&D at Hoffman La Roche, a...
Read more >>

Dr Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech. He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Sanjay was Senior Vice President of R&D at Hoffman La Roche, and Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology. He has held CEO and CMO positions in biotech with experience of successful Nasdaq IPO (Annexon), acquisition (MiroBio by Gliead), venture fundraising (Series A, B, D rounds), and multiple industry partnerships. Sanjay has been instrumental in the development of several approved medicines, including Risdiplam, Emgality, Faricimab, Cymbalta, Aimovig and Deucravacitnib. Sanjay completed his residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at Johns Hopkins. He graduated in medicine at St. Bartholomew’s Hospital (UK’s oldest hospital founded in 1123) and holds a First Class honors BSc degree from St. Mary’s Hospital, London in Pathology & Basic Medical Sciences (Immunology).

Mr. Ehud Barak

Former Prime Minister of Israel. Serves on a number of public and private boards of directors and advisory boards.

Former Prime Minister of Israel. Serves on a number of public and private boards of directors and advisory boards.

Mr. David Ben-Ami

Over 25 years of experience in the health sector. His activities span from management to business development, corporate strategy, and entrepreneurship in the life sciences industry. Mr. Ben-Ami was the Founder and Executive Chairman of NASDAQ-listed company Macrocure Ltd. from 2008 to 2016.

Over 25 years of experience in the health sector. His activities span from management to business development, corporate strategy, and entrepreneurship in the life sciences industry. Mr. Ben-Ami was the Founder and Executive Chairman of NASDAQ-listed company Macrocure Ltd. from 2008 to 2016.

Dr. Avraham Kadar

Avraham Kadar, M.D., is a pediatrician and National Institutes of Health (NIH)-trained immunologist, and the Founder, Chairman and Chief Executive Officer of BrainPOP, an internet company that includes the award-winning animated online educational platform BrainPOP, and the pioneering dynamic digital mark...
Read more >>

Avraham Kadar, M.D., is a pediatrician and National Institutes of Health (NIH)-trained immunologist, and the Founder, Chairman and Chief Executive Officer of BrainPOP, an internet company that includes the award-winning animated online educational platform BrainPOP, and the pioneering dynamic digital marketing and rich media solutions AditAll, LLC and Dynamic Video, LLC.

Mr. Jay Kranzler

Founder, CEO, Board Member, and Advisor to leading life science companies for over 30 years. Most recently served as Global Head - External R&D Innovation - Neuroscience, Pain, and Sensory Disorders for Pfizer.

Founder, CEO, Board Member, and Advisor to leading life science companies for over 30 years. Most recently served as Global Head - External R&D Innovation - Neuroscience, Pain, and Sensory Disorders for Pfizer.

James M. Mackay, Ph.D.

James Mackay, PhD, is the Founder and Chief Executive Officer of Kateran Consulting and has over 25 years of drug development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. Prior to founding Kateran Consulting, Ja...
Read more >>
James Mackay, PhD, is the Founder and Chief Executive Officer of Kateran Consulting and has over 25 years of drug development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. Prior to founding Kateran Consulting, James was Founder, President and Chief Executive Officer of Aristea Therapeutics, a clinical stay immunology biotech that raised $138m.    James also held the CEO position at Ardea Biosciences, Inc., following the company’s acquisition by AstraZeneca in 2012. James was instrumental to setting up an innovative model for Ardea Biosciences that retained the biotech’s independence and accountability for the development of the gout franchise while also developing a synergistic and collaborative relationship with the parent company, AstraZeneca. Prior to Ardea, James held senior executive positions at AstraZeneca where he led the development and commercialization of drugs across a range of therapy areas. and managed significant global functional departments.
James plays a pivotal role in the San Diego Ecosystem and currently sits on the Board and Executive Committee of CONNECT and sits on the Board of BIOCOM. He is a former Board member of the San Diego Economic Development Corporation (EDC). James holds a BS in Genetics and PhD in Medical Genetics from Aberdeen University, Scotland.